What it's for (Indications)
- Fluvastatin, available in immediate-release (Lescol) and extended-release (Lescol XL) formulations, is indicated as an adjunct to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), and triglycerides (TG) in adult patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb).
- It is also used to increase high-density lipoprotein cholesterol (HDL-C).
- For the primary prevention of cardiovascular events, fluvastatin is indicated to reduce the risk of non-fatal myocardial infarction and the need for revascularization procedures in adult patients with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD.
- In secondary prevention, it is used in patients with established CHD to slow the progression of coronary atherosclerosis.
- Additionally, it is indicated for the reduction of major adverse cardiac events in patients following percutaneous coronary intervention (PCI).
- The drug's efficacy in pediatric patients (9-16 years) with heterozygous familial hypercholesterolemia (HeFH) has also been established as an adjunct to diet to reduce TC, LDL-C, and apoB when diet alone has proven insufficient.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of fluvastatin must be individualized based on the patient's lipid levels, therapeutic goals, and response to treatment. For adult patients, the recommended starting dose for immediate-release capsules (Lescol) is typically 20 mg or 40 mg once daily, administered in the evening. For the extended-release tablets (Lescol XL), the usual starting dose is 80 mg once daily, taken at any time of day. Lipid levels should be assessed within 4 weeks after initiation of treatment or titration, and the dose should be adjusted accordingly. The maximum recommended dose for immediate-release fluvastatin is 80 mg per day, which can be given as 40 mg twice daily or 80 mg once daily in the evening. The maximum recommended dose for extended-release fluvastatin is 80 mg once daily. For pediatric patients aged 9-16 years with HeFH, the recommended starting dose is 20 mg once daily in the evening, with a maximum dose of 40 mg once daily. No dose adjustment is generally required for patients with mild to moderate renal impairment, though caution is advised in severe cases. However, fluvastatin is contraindicated in active liver disease. |
Safety & Warnings
Common Side Effects
- As with all medications, fluvastatin can cause various side effects, ranging from common and generally mild to rare but potentially serious.
- Common side effects reported during clinical trials include headache, nausea, abdominal pain, dyspepsia, diarrhea, and fatigue.
- Less commonly, patients may experience insomnia, rash, and arthralgia.
- Of greater clinical concern are serious adverse events associated with statin therapy.
- These include myopathy, characterized by muscle pain, tenderness, or weakness, which can, in rare instances, progress to rhabdomyolysis, a severe condition involving extensive muscle breakdown, acute renal failure, and potentially death.
- Patients should be advised to report any unexplained muscle symptoms promptly.
- Elevated liver transaminases, indicating potential hepatotoxicity, have also been observed; persistent elevations warrant dose reduction or discontinuation.
- Other serious but rare adverse events include new-onset diabetes mellitus, cognitive impairment (e.
- g.
- , memory loss, confusion) which is typically reversible, and hypersensitivity reactions such as angioedema or anaphylaxis.
- Regular monitoring and patient education are crucial for early detection and management of these potential side effects.
Serious Warnings
- Black Box Warning: Fluvastatin (Lescol, Lescol XL) does **NOT** carry a formal FDA Black Box Warning. However, due to the critical nature of potential adverse events associated with statin therapy, a comprehensive understanding of severe risks is paramount. This section serves as a **Serious Warnings** notice to highlight the most significant safety concerns. **Serious Warnings: Myopathy and Rhabdomyolysis / Liver Dysfunction** **Myopathy and Rhabdomyolysis:** Fluvastatin therapy has been associated with myopathy, which is characterized by muscle pain, tenderness, or weakness, and accompanied by a creatine kinase (CK) level greater than ten times the upper limit of normal (ULN). In rare instances, myopathy can progress to rhabdomyolysis, a severe and potentially fatal condition involving extensive muscle breakdown leading to acute renal failure, primarily through myoglobinuria. The risk of myopathy/rhabdomyolysis is dose-related and significantly increased by concurrent use of fluvastatin with certain drugs, including fibrates (e.g., gemfibrozil), niacin in lipid-lowering doses (≥1 g/day), cyclosporine, and colchicine. Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if myopathy is diagnosed or suspected, or if CK levels are markedly elevated. **Liver Dysfunction:** HMG-CoA reductase inhibitors, including fluvastatin, can cause biochemical abnormalities of liver function. Persistent elevations of serum transaminases (ALT or AST) exceeding three times the upper limit of normal (3x ULN) have been reported. It is crucial to perform liver function tests (LFTs) prior to the initiation of fluvastatin therapy, and thereafter as clinically indicated, particularly if symptoms suggestive of liver injury develop. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, fluvastatin therapy should be immediately interrupted or discontinued. Patients with active liver disease or unexplained persistent transaminase elevations are contraindicated for fluvastatin use.
- Fluvastatin carries several important warnings that healthcare providers and patients must consider.
- **Liver Dysfunction:** Statins, including fluvastatin, can cause biochemical abnormalities of liver function.
- Persistent elevations of serum transaminases (>3 times the upper limit of normal [ULN]) have occurred.
- It is recommended to perform liver function tests (LFTs) prior to initiating fluvastatin and periodically thereafter, or as clinically indicated.
- If transaminase levels rise to >3 times ULN and persist, the dosage should be reduced or the drug discontinued.
- **Myopathy and Rhabdomyolysis:** There is a risk of developing myopathy, which can manifest as muscle pain, tenderness, or weakness.
- This can progress to rhabdomyolysis, a potentially life-threatening condition involving severe muscle necrosis and acute kidney injury.
- The risk is increased with higher doses, advanced age, renal impairment, hypothyroidism, and co-administration with certain drugs such as fibrates, niacin (>1 g/day), cyclosporine, or colchicine.
- Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, especially if accompanied by malaise or fever.
- **New-Onset Diabetes Mellitus:** Statins have been shown to increase HbA1c and fasting serum glucose levels.
- While the cardiovascular benefits generally outweigh this small risk, patients at high risk for diabetes should be monitored.
- **Cognitive Impairment:** Rare post-marketing reports of cognitive impairment (e.
- g.
- , memory loss, forgetfulness, amnesia, confusion) have been associated with statin use.
- These symptoms are generally non-serious, reversible upon discontinuation, and not progressive.
- **Interstitial Lung Disease:** Very rare cases reported with statins, characterized by dyspnea, non-productive cough, and general health deterioration.
- **Drug Interactions:** Fluvastatin is primarily metabolized by CYP2C9 and to a lesser extent by CYP3A4.
- Concomitant administration with inhibitors of these enzymes may increase fluvastatin plasma concentrations.
- Significant interactions can occur with drugs like cyclosporine, gemfibrozil, niacin (lipid-lowering doses), and warfarin, requiring careful monitoring and potential dose adjustments.
How it Works (Mechanism of Action)
Fluvastatin exerts its lipid-lowering effects by competitively inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, an enzyme pivotal in the cholesterol biosynthesis pathway. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in hepatic cholesterol synthesis. By blocking HMG-CoA reductase, fluvastatin significantly reduces the intracellular supply of cholesterol within liver cells. This depletion of hepatic cholesterol triggers a compensatory up-regulation of low-density lipoprotein (LDL) receptors on the surface of hepatocytes. The increased expression and activity of LDL receptors lead to enhanced uptake and catabolism of circulating LDL-C particles from the bloodstream. Beyond its primary effect on LDL-C, fluvastatin also reduces the hepatic synthesis of very low-density lipoprotein (VLDL), thereby lowering triglyceride levels. Concomitantly, a modest increase in high-density lipoprotein cholesterol (HDL-C) is often observed. The overall consequence of these actions is a comprehensive improvement in the lipid profile, reducing atherogenic lipoproteins and potentially mitigating the progression of atherosclerotic disease. Additionally, like other statins, fluvastatin possesses pleiotropic effects, including anti-inflammatory, antioxidant, and endothelial function-improving properties, which contribute to its overall cardiovascular protective benefits independent of lipid lowering.